TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00714090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed
Description: active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine
Description: active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine
Description: sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
Study: NCT00822822

Intervention type: BEHAVIORAL
Intervention: First Questionnaire
Description: Complete questionnaire before completing health history

Intervention type: BEHAVIORAL
Intervention: Health History
Description: Complete electronic health history

Intervention type: BEHAVIORAL
Intervention: Second Questionnaire
Description: Complete questionnaire after completing electronic health history
Study: NCT05512442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the centric relation
Description: All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the centric relation
Description: All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.
Study: NCT01828697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose nadroparin
Description: Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose nadroparin
Description: Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose enoxaparin
Description: Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose enoxaparin
Description: Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose dalteparin
Description: Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose dalteparin
Description: Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed low dose tinzaparin
Description: Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate dose tinzaparin
Description: Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily.
Study: NCT03808805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Description: oral therapy - daily dose - 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine 25mg
Description: oral therapy - daily dose - 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Hydroxyzine
Description: oral therapy - daily dose - 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aprepitant
Description: oral therapy - daily dose - 14 days
Study: NCT01442857

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: High resolution MRI of the brachial plexus
Study: NCT04165330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
Study: NCT03041025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
Study: NCT04081519

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Add-on sham rTMS
Description: 15 additional sessions of sham rTMS over DLPFC or LPC
Study: NCT02624206

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice A
Description: Subjects to be given juice daily for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice B
Description: Subjects to be given juice daily for 3 weeks.
Study: NCT03195920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Lithotripsy System
Description: The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
Study: NCT01349660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 orally (PO) once daily
Study: NCT01668277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% NaCl
Study: NCT04702711

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02400411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat bread
Study: NCT03041025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9 percent weight per volume sodium chloride).
Study: NCT00155402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue fibrin glue application (Tisseel)
Description: Apply several droplets within several seconds to several minutes
Study: NCT04610255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigned Interventions
Description: * Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic myofascial release
Description: DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week.
Study: NCT03770403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: Intravenous administration of ARGX-113
Study: NCT03437603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
Study: NCT04030000

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel/Carboplatin
Description: IV paclitaxel in combination with IP carboplatin

Intervention type: RADIATION
Group type: OTHER
Intervention: Pelvic radiation therapy
Description: EBRT and vaginal brachytherapy
Study: NCT03591900

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: insulin pump/CGMS
Description: A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: insulin pump/CGMS
Description: A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009).
Study: NCT04070794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)
Description: Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)
Description: Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
Study: NCT03185546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NNC Spectrum Cigarette
Description: Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NNC Spectrum Cigarette
Description: Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NNC Spectrum Cigarette
Description: Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NNC Spectrum Cigarette
Description: Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Spectrum Cigarette
Description: Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Spectrum Cigarette
Description: Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Spectrum Cigarette
Description: Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Spectrum Cigarette
Description: Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
Study: NCT03041025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9 percent weight per volume sodium chloride).
Study: NCT04368624

Intervention type: OTHER
Intervention: Skin Tape
Description: Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.

Intervention type: OTHER
Intervention: Skin Tape
Description: Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
Study: NCT04781205

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mutation arrays, NGS panels, GWAS, WES, WGS,
Description: DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable monitors
Description: test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
Study: NCT01533805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises with stabilization
Description: This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Pilates
Description: This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
Study: NCT03247920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Intravenous antibiotic therapy following local protocol
Study: NCT04572659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention
Description: Several couples attended a total of six group psychotherapy sessions conducted by a psychologist. Between 4 and 7 couples were treated in each group session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Couple psychosocial intervention
Description: The couple attended a total of six psychotherapy sessions conducted by a psychologist. Each couple was attended particularly.
Study: NCT03790345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: Adjuvant daily treatment with 200mg of pyridoxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobalamin
Description: Adjuvant daily treatment with 2mg of cobalamin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Adjuvant daily treatment with placebo
Study: NCT00794963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan
Description: The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.

Intervention type: OTHER
Group type: OTHER
Intervention: As selected by community physician
Description: As selected by community physician
Study: NCT02010320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer dosing
Description: Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose determination
Description: Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
Study: NCT03776422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile self-help intervention
Description: Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
Study: NCT04591717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
Study: NCT03520517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-0223
Description: BHV-0223, 40 mg BID
Study: NCT00486395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP administered via Bubble method or Infant Flow Driver

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Volume guarantee strategy
Study: NCT02136290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prepackaged meals
Description: Portion-controlled prepackaged meals

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care dietary counseling
Study: NCT03594552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_15
Description: Single oral dose (15mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)
Study: NCT01136174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for cohort 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
Study: NCT01042522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV
Study: NCT03594552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)
Study: NCT01042522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03594552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_30
Description: Single oral dose (30mg)
Study: NCT02400411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine